CLE-400(CLE-400) - 药物靶点：H4 receptor x SSTR4 x α2A-AR_在 …
CLE-400: 一种H4 receptor激动剂、SSTR4激动剂、α2A-AR激动剂药物，由Clexio Biosciences Ltd. (Clexio Biosciences Ltd.)公司最早进行研发，目前全球最高研发状态为临床2期，作用机制: …
The analgesic activity of CLE-400 at 3 doses administered topically (BID) for 14 days was evaluated on PNT-induced neuropathic pain in pigs. Von Frey (VF) assessment was used to …
• CLE-400 is a topical gel targeting peripheral α2-adrenergic receptors in the skin. Activation of these receptors could produce . anti pruritic as well as analgesic effects. by inhibiting the …
Topical application of CLE-400 significantly suppressed chloroquine-induced scratching behaviors at all dose levels • 3 oses of CLEd -400 administered topically once daily for 5 days (last …
SSTR4 - 药物、适应症、专利 - 智慧芽新药情报库
This is a Phase 2, randomized, double-blind, vehicle-controlled study to assess the efficacy and safety of CLE-400 topical gel for the treatment of chronic pruritus in adult subjects with …
LB787 CLE-400: A potent alpha-2 adrenergic receptor agonist for …
CLE-400 is an aqueous gel of detomidine that is being developed for the topical treatment of itch. Detomidine is a potent α2-adrenergic receptor (α2-AR) agonist. α2-AR have been shown to be …
CLE-400 和 车辆 在 患有感觉异常（NP）的成人受试者的慢性瘙痒 …
2024年2月8日 · 一项随机、双盲、载体对照、多中心、平行设计、2 期研究，旨在评估 CLE-400 外用凝胶治疗成人感觉异常疼痛受试者慢性瘙痒的疗效和安全性. 这是一项 2 期、随机、双盲 …
Trial | NCT06262607
Study to assess the efficacy and safety of CLE-400 topical gel applied once daily for the treatment of moderate-severe chronic pruritus in adult subjects with NP. The study comprises a …
H4 receptor x α2A-AR x SSTR4 - Drugs, Indications, Patents
A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-Design, Phase 2 Study to Assess the Efficacy and Safety of CLE-400 Topical Gel for the Treatment of Chronic Pruritus …
CLE-400 Drug Profile - Ozmosi
Clexio is developing CLE-400, a topical gel formulation containing a non-opioid, non-steroid, analgesic compound, to treat patients suffering from peripheral neuropathic pain. CLE-400 is a …